


However, there exists a strong need for novel Toll-Like receptor modulators having preferred selectivity, higher potency, and an improved safety profile compared to the compounds of the prior art.

In accordance with the present disclosure, a compound of formula (I, II, or III) is
5 provided




or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric form, solvate or polymorph thereof, wherein

R₁ is C₁₋₆ alkyl optionally substituted by one or more substituents independently
10 selected from alcohol or C₁₋₃alkoxy;

R₂ is selected from hydrogen, fluorine, C₁₋₃ alkyl, cyclopropyl, -CF₃, C₁₋₃alkoxy or nitrile.

In accordance with the present disclosure, in one aspect, there is provided a compound of formula (I), (II), or (III) having the structure




or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof, wherein


R₁ is C₁₋₆ alkyl substituted by one or more substituents independently selected from alcohol or C₁₋₃alkoxy; and

R₂ is selected from hydrogen, fluorine, C₁₋₃ alkyl, cyclopropyl, -CF₃, C₁₋₃alkoxy or
20 nitrile.

Preferred compounds of formulas I and II include the structures below:




The most preferred compound, of formula III, has the following structure:



- 5 The compounds of formula (I, II, III) and their pharmaceutically acceptable salts, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof have activity as pharmaceuticals, in particular as modulators of Toll-Like Receptors 7 and 8 (especially TLR 8).

Claims

1. A compound of formula (I), (II) or (III) having the structure




or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof, wherein

R₁ is C₁₋₆ alkyl substituted by one or more substituents independently selected from alcohol or C₁₋₃alkoxy; and

R₂ is selected from hydrogen, fluorine, C₁₋₃ alkyl, cyclopropyl, -CF₃, C₁₋₃alkoxy or nitrile.

2. A compound according to claim 1 having the structure



3. A pharmaceutical composition comprising a compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof according to claim 1 or any of the structures according to claim 2 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

4. A compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof according to claim 1 or 2 or a pharmaceutical composition according to claim 3 for use as a medicament.

5. A compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof according to claim 1 or 2, or a pharmaceutical composition according to claim 3 for use in the treatment of a disorder in which the modulation of TLR7 and /or TLR8 is involved, preferably TLR8.
6. Use of a compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof according to claim 1 or 2 in the manufacture of a medicament for the treatment of viral infections, immune or inflammatory disorders.